Drug intelligence / Profile preview

CG-EY1

Development stage: Preclinical
Lead developer: Lerna Biopharma
Modality: Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
Administration: Ophthalmic

Overview

CG-EY1 is a preclinical-stage small interfering RNA (siRNA) therapeutic being developed by Lerna Biopharma (formerly Cargene Therapeutics) for the treatment of hereditary retinal dystrophy. As an siRNA-based therapy, it is designed to utilize the RNA interference (RNAi) pathway to silence the expression of a specific, though currently undisclosed, disease-causing gene in the retina. The drug is part of Lerna Biopharma's ophthalmic pipeline, which leverages the company's expertise in oligonucleotide delivery and stabilization to address genetic disorders of the eye.

Beyond the preview

Go deeper on CG-EY1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CG-EY1.

Explore the full profile